“This is a game changer for companies looking for a Chair or NED. A powerful FREE tool.”
Anthony Chadwick CEO Alpha Vet International
Register to post jobs to our network FREE
You're all set
You’re about to join an exclusive membership club of highly skilled and aspiring Non-Exec’s. No up-sells, no gimmicks, just the expert tools to develop your portfolio career.Only £149
LIMITED TIME OFFER!
Send message to The VirtualNonExec Team
Send message to Mike
Upgrade to premium to unlock job access
We do not scrape jobs from websites like others. You have my personal guarentee.
I am Mike Karim the CEO and co-founder of Oxford Endovascular Ltd, a spinout from Oxford University. I am open to Non-Executive Director roles to help other companies on their journeys.
My company is developing a revolutionary medical device, a next generation flow diverter, to treat brain aneurysms; a life-threatening disease affecting 1 in 50 persons in a strongly growing market valued over $1 billion.
I have raised over $20m from investors to support the company’s development activities and we have won significant non-dilutive grants from the European Commission’s prestigious Horizon 2020 program as well as Innovate UK.
I have over 30 years growing international businesses in large corporations & start-ups (Pharma w Upjohn Pharma, Boston Sci, then Lombard Medical, Heartware & Aptus Endosystems, which were sold to Medtronic
I mentor budding entrepreneurs, is a panellist at industry conferences, sits on the ‘Medfit’ organisation steering committee as well as being a sub-board member of the Association of British Healthcare Industries (ABHI).
I studied Pre-Clinical Medicine, Physiology & Pharmacology at Southampton University and hold an MBA from Henley Business School, UK.
Mike's Career History
Oxford Endovascular Ltd
CEO & Director of the Board
October 2015 - Ongoing
Oxford Endovascular is a spin-out from Oxford University, working to treat brain aneurysms.
OxiFlow™️ is a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, reducing the risk of adverse events. It conforms better to blood vessels making more patients treatable and has the capability to become the market leading device.
Conceived by a world-renowned physician who pioneered the treatment of aneurysms over the last 30 years and an expert in ‘Origami Engineering’, it has patents in Europe, US, China & Japan.
Aptus Endosystems Inc
Senior Director International
September 2014 - July 2015
Global Director Market Development
June 2010 - September 2014
Lombard Medical Ltd
Global Director Sales & Marketing
June 2007 - June 2010
Boston Scientific Inc
May 1995 - May 2007
Upjohn Pharmaceuticals Ltd
Hospital Specialist and Regional Manager
August 1991 - March 1995